- Home
- HLX vs MNKD Comparison
HLX vs MNKD Comparison
Compare HLX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLX
- MNKD
- Stock Information
- Founded
- HLX 1979
- MNKD 1991
- Country
- HLX United States
- MNKD United States
- Employees
- HLX N/A
- MNKD N/A
- Industry
- HLX Oilfield Services/Equipment
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- HLX Energy
- MNKD Health Care
- Exchange
- HLX Nasdaq
- MNKD Nasdaq
- Market Cap
- HLX 1.4B
- MNKD 1.5B
- IPO Year
- HLX 1997
- MNKD 2004
- Fundamental
- Price
- HLX $7.90
- MNKD $5.76
- Analyst Decision
- HLX Strong Buy
- MNKD Buy
- Analyst Count
- HLX 4
- MNKD 6
- Target Price
- HLX $13.33
- MNKD $8.92
- AVG Volume (30 Days)
- HLX 1.1M
- MNKD 1.7M
- Earning Date
- HLX 02-24-2025
- MNKD 02-26-2025
- Dividend Yield
- HLX N/A
- MNKD N/A
- EPS Growth
- HLX N/A
- MNKD N/A
- EPS
- HLX 0.05
- MNKD 0.08
- Revenue
- HLX $1,338,584,000.00
- MNKD $267,200,000.00
- Revenue This Year
- HLX $2.97
- MNKD $44.15
- Revenue Next Year
- HLX $3.54
- MNKD $19.65
- P/E Ratio
- HLX $166.85
- MNKD $72.65
- Revenue Growth
- HLX 7.74
- MNKD 51.35
- 52 Week Low
- HLX $7.76
- MNKD $3.47
- 52 Week High
- HLX $13.05
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- HLX 35.50
- MNKD 48.03
- Support Level
- HLX $8.04
- MNKD $5.32
- Resistance Level
- HLX $8.46
- MNKD $5.65
- Average True Range (ATR)
- HLX 0.25
- MNKD 0.18
- MACD
- HLX 0.03
- MNKD 0.03
- Stochastic Oscillator
- HLX 19.29
- MNKD 81.48
About HLX Helix Energy Solutions Group Inc.
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments Well Intervention, Robotics, Production Facilities and Shallow Water Abandonment. the Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the US.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.